Drugs and patents in ATC class D05B - ANTIPSORIATICS FOR SYSTEMIC USE

Last updated: June 18, 2026

ATC D05B covers systemic antipsoriatics, primarily oral small molecules and biologics (with some overlap in dosing-adjacent segments). The market is dominated by TNF-alpha inhibitors (less “new” patent runway), IL-23/IL-17 pathway biologics (current growth and the heaviest late-stage patenting), and oral agents (methotrexate largely off-patent; apremilast and JAK/other oral classes with more time-dependent exclusivity). Across the class, patent strategy is split between (1) active ingredient patents (composition, polymorph, salts) and (2) secondary patents (formulations, dosing regimens, treatable subpopulations, and manufacturing). Generic or biosimilar entry timing is driven by FDA exclusivities plus patent expiry and Paragraph IV litigation windows for small molecules, and by biologics licensing/12-year/4-year exclusivity and reference product patent estates for biosimilars.

This report maps the market mechanics and patent-landscape dynamics for ATC D05B at the program level, and outlines where exclusivity and the patent estate are most likely to delay or accelerate entry.

Which systemic antipsoriatics drive ATC D05B market dynamics?

ATC D05B “antipsoriatics for systemic use” is operationally anchored by three clusters:

Biologics targeting IL-23/IL-17 and TNF-alpha
- Market behavior: high switching barriers through administration channel, patient response durability, payer pathway design, and safety switching.
- Patent behavior: “thick” late-life estates via variant proteins, dosing, manufacturing controls, and post-approval amendments.
Oral small molecules
- Market behavior: prescriber adoption tied to speed of onset, monitoring burden, comorbidity fit, and payer restrictions on biologics.
- Patent behavior: compound, polymorph/salt, crystal form, and formulation patents drive the last mile; exclusivity can be extended via line extensions and combination products.
Older systemic agents
- Methotrexate and other older drugs are typically outside meaningful IP exclusivity in major markets.
- Market behavior: stable share but constrained by toxicity management and biologic/payer preferences.

What biologic subclasses win psoriasis systemic share under payer rules?

IL-23 and IL-17 pathway therapies generally show the strongest current commercial momentum in many markets, with payer step edits increasingly favoring newer mechanisms where outcomes data and dosing convenience allow.
TNF-alpha therapies face reduced incremental uptake and more competitive pricing pressure as biosimilar penetration rises.

What payer and hospital formularies do to systemic antipsoriatics demand?

Formularies tend to segment by:
- Lines of therapy (first-line biologic vs second-line after phototherapy or conventional agents)
- Comorbidity (psoriatic arthritis coexistence often dictates payer routing)
- Route convenience (self-injectable vs clinic-administered)
These rules can extend “effective” exclusivity beyond legal expiry because switching cycles, prior auth criteria, and response documentation create inertia.

What patents protect systemic antipsoriatics in ATC D05B?

Patent coverage in D05B tends to follow repeatable structures. For each marketed agent, the estate typically includes:

Composition-of-matter for the active ingredient (protein or small molecule).
Manufacturing-process patents (especially for biologics) covering cell lines, purification steps, and formulation controls.
Formulation and device patents (injectable presentation, dosing volume/concentration, viscosity, syringe design).
Method-of-use patents (specific dosing regimens, patient subgroups, endpoints, and combinations).
Polymorph/crystal form and salt patents (small molecules).
Combination therapy patents (e.g., with topical agents, phototherapy adjuncts, or other systemic drugs).

How many patents usually cover a D05B systemic antipsoriatic product?

Modern biologic estates often show dozens of listed patents per reference product when including secondary filings and manufacturing variants.
Oral small molecules often show a narrower but still material cluster: compound + one or more formulation/polymorph + dosing regimen.

Which patent “types” most often delay generic entry for small molecules?

Active ingredient composition patents.
Polymorph/crystal form patents and salt forms.
Extended-release or specific dosing form patents.
Method-of-use patents tied to labelled regimens (these matter more when FDA labeling permits them to be asserted effectively in a Paragraph IV strategy).

Which patent “types” most often delay biosimilar approval and launch?

Patent estates on:
- the biologic molecule itself (sequence/structure claims or variant claims)
- manufacturing process and quality attributes (hard-to-design-around controls)
- formulation, stability, and delivery device presentation
Even after FDA biosimilar approval, launch can be blocked by patent infringement findings or settlement agreements.

When does exclusivity end for systemic antipsoriatics in ATC D05B?

Exclusivity timing differs by product type:

FDA small-molecule exclusivity

New chemical entity (NCE) exclusivity and new clinical investigations exclusivity can add periods to patent expiry depending on the filing history.
Patent expiry drives Paragraph IV windows for generics; exclusivity can prevent approval even if a generic is ready to challenge.

FDA biologic exclusivity

Biologic exclusivity is governed by:
- 12-year reference product exclusivity for approval
- 4-year waiting period for biosimilar “data exclusivity” reduction on certain submissions
Biosimilar applications can be filed before expiry, but approval and commercial launch timing often track patent litigation outcomes.

Market effect of “effective exclusivity”

Even after legal exclusivity ends, entry is delayed by:
- payer contracting timelines
- substitution policies and switching evidence requirements
- manufacturing capacity ramp and lot release controls (especially for biologics)

What is the Orange Book status of systemic antipsoriatics (D05B) and how does it drive generic risk?

Small molecules in D05B are listed in the FDA Orange Book; biologics are not listed in Orange Book in the same way, so biosimilar risk must be assessed via the reference product’s patent estate for the relevant biologic licensing applications.

What to look for in Orange Book listings for D05B

Patent expiration dates for:
- Drug substance (active ingredient)
- Drug product (formulation)
- Methods of use
Whether patents are coded as:
- B (product)
- D (method of use)
- A (drug substance)
Listing depth:
- multiple expiries create staggered barriers to approval, which can extend the period in which generics are forced into “at-risk” litigation strategies.

How Paragraph IV challenges map to generic entry

A generic filing under Paragraph IV effectively selects which patent(s) to challenge.
Courts and settlements can lead to:
- delayed launch until final resolution
- authorized entry at a later date
- carve-outs allowing partial entry only if certain claims are designed around

How do patent estates differ between IL-23 inhibitors and IL-17 inhibitors in systemic psoriasis?

Across IL-23 and IL-17 classes, patent estates show different “pressure points”:

IL-23 inhibitors

Claims often concentrate on:
- antibody/protein sequence and variants
- manufacturing and glycoengineering attributes
- specific dosing regimens and patient response endpoints
Late-stage filings frequently target formulation stability, injection parameters, and device presentation.

IL-17 inhibitors

Similar structure but with:
- additional line extensions for alternate dosing schedules (where label supports them)
- formulation patents related to viscosity, concentration, and stability over shelf-life
Biosimilar risk depends heavily on whether reference product patents are strong on molecule and manufacturing.

What patent litigation affects systemic antipsoriatics, and how do settlements shift entry dates?

Generic and biosimilar entry for D05B drugs often hinges on litigation and settlement rather than on legal expiry alone.

Typical settlement patterns

Staggered settlements tied to:
- patent expiry dates across multiple patents
- court findings on specific claims
- design-around conditions for formulation or dosing
“No-older-than” settlement structures that bind both parties on launch timing even if some patents expire earlier.

What litigation timing means for R&D planning

If a competitor is actively challenging patents, the market impact is measured in:
- launch probability by quarter
- likely settlement position
- whether the challenger is prepared for at-risk launch if no settlement occurs

What generic entry risks exist for oral systemic antipsoriatics in ATC D05B?

Oral systemic psoriasis drugs face lower biosimilar-specific constraints but still encounter:

composition-of-matter and polymorph barriers
formulation and method-of-use patents that can delay approval

Generic risk drivers

Strength of the active ingredient patent family (compound core and immediate variants).
Breadth of polymorph/crystal/salt patents.
Whether the method-of-use claims are enforceable against the generic’s label-driven indication.

What “design-around” looks like in D05B oral generics

Alternative polymorph or salt selection can be used to avoid certain composition patents.
Reformulation (different excipient profile or solid-state form) can reduce infringement risk on product/formulation claims.
Dosing regimen changes can matter for method-of-use claims, but only if they do not conflict with FDA-required labeling.

How do biosimilar risk profiles vary across systemic antipsoriatics?

Biosimilar risk is driven by three factors:

Patent estate breadth
- manufacturing process patents are often the hardest to design around.
Settlement behavior
- biosimilar sponsors frequently seek predictable entry through multi-patent settlement structures.
Indication strategy
- biosimilars may launch for a subset of indications first if it reduces patent exposure.

What increases biosimilar launch likelihood?

Narrow reference product patents with limited manufacturing claim strength.
Weakness or non-infringement positions on core claims.
Settlement agreements that establish earlier launch windows.

What increases biosimilar launch delay risk?

Multiple overlapping patent families spanning molecule, variants, and manufacturing controls.
Court outcomes that affirm broad claim interpretations.

How does ATC D05B’s competitive landscape shift when patents expire?

Patent expiry translates into market share movement in predictable ways:

Small molecules: generics compress unit pricing; payer benefit designs often encourage rapid switching when no administration penalty exists.
Biologics: biosimilar share gains depend on:
- switching incentives
- physician willingness to change stable patients
- payer controls on procurement and substitution

Where patent cliffs hurt revenue the most

When a product has:
- concentrated revenue in a single mechanism with little overlap
- limited line extensions
- high reimbursement sensitivity to net pricing
Revenue exposure also rises where competitors have secured manufacturing scale and have settlement paths that allow near-interval launches.

What formulations are protected by patents in systemic antipsoriatics (D05B)?

Formulation protection is a consistent lever for extending exclusivity, especially for biologics and oral solid forms.

Biologics: formulation and delivery patents

Concentration and viscosity targets.
Stabilizing excipients.
Storage and shipping stability.
Syringe or autoinjector compatibility where claimed.

Oral small molecules: solid-state and release patents

Polymorph/cocrystal selection to control solubility and bioavailability.
Salt form selection.
Coating/release profiles.
Stability and manufacturing process controls tied to specific solid-state outcomes.

Which companies are likely to be challenging systemic antipsoriatics patents?

In D05B, challengers typically fall into:

Generic sponsors pursuing Paragraph IV filings for Orange Book-listed small molecules.
Biosimilar sponsors building reference-product patent strategy for biologics.

The competitive outcome is determined less by the number of filings and more by:

whether the challenger has credible non-infringement or invalidity positions
whether settlement creates a launch window earlier than the full patent expiry sequence.

Key patent estate and market timing framework (how to run the playbook)

Use the following framework to evaluate D05B products for licensing, investment, or litigation readiness:

Define the product type
- small molecule vs biologic
Map FDA regulatory lane
- Orange Book patents for small molecules; biosimilar patent estate for biologics
Build a patent timeline
- earliest composition expiry
- formulation/product expiry
- method-of-use expiry
- expected litigation outcomes and settlement windows
Identify the “entry blocker”
- the last-to-expire, highest-likelihood-enforced patent
Model payer and switching impact
- effective exclusivity can extend beyond legal expiry

Key Takeaways

ATC D05B systemic antipsoriatics are shaped by two dominant mechanisms: biologics (IL-23/IL-17/TNF) and oral small molecules, each with distinct IP and regulatory timing dynamics.
Patent estates for biologics are typically broader and manufacturing-focused; biosimilar launch timing often tracks patent litigation and settlement rather than approval alone.
For oral small molecules, Orange Book listing depth and method-of-use claims materially affect Paragraph IV generic entry risk.
Effective market exclusivity is frequently extended by payer access design and switching inertia even after legal expiry.

FAQs

1) Which patents most commonly block generic approval for systemic antipsoriatics?

Active ingredient composition and polymorph/crystal form patents, followed by formulation and method-of-use patents tied to labelled regimens.

2) What is the Orange Book listing strategy for small-molecule antipsoriatics in D05B?

Track drug substance, drug product, and method-of-use patents and note staggered expiries and patent codes to assess the last blocking patent.

3) How do biosimilar settlements typically change launch timing for IL-23 or IL-17 psoriasis drugs?

They usually create a predictable launch window based on selected patents and stipulate design-around conditions, often accelerating or delaying entry versus raw expiry dates.

4) Do method-of-use patents matter for generic antipsoriatics?

Yes when the generic is marketed with the same indication and dosing regimen and the method claims are enforceable against label-driven use.

5) What factors delay biosimilar market share gains after FDA approval?

Switching policies, payer formulary constraints, physician adoption, and the time needed to establish supply reliability and real-world interchangeability.

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. Biosimilar Biological Products. U.S. Food and Drug Administration.
FDA. CDER Drug Development and Drug Interactions Glossary: Exclusivity. U.S. Food and Drug Administration.

Subclasses in ATC: D05B - ANTIPSORIATICS FOR SYSTEMIC USE